Trials / Completed
CompletedNCT02293993
Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the tolerability and pharmacokinetics of SGI-110 when administered subcutaneously to Japanese patients with acute myeloid leukemia (AML).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGI-110 |
Timeline
- Start date
- 2015-01-07
- Primary completion
- 2017-06-14
- Completion
- 2019-05-31
- First posted
- 2014-11-19
- Last updated
- 2021-03-05
- Results posted
- 2021-03-05
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02293993. Inclusion in this directory is not an endorsement.